Dr. Weckstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 Pleasant St
Concord, NH 03301Phone+1 603-314-6879
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
- Tufts Medical CenterResidency, Internal Medicine, 1986 - 1989
- Virginia Commonwealth University School of MedicineClass of 1986
Certifications & Licensure
- NH State Medical License 1998 - 2026
- MA State Medical License 1988 - 2025
- NY State Medical License 1995 - 2002
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2014
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01 - 4 citationsPRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus
Journal of Clinical Oncology. 2024-04-01 - 1 citationsCetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag
The Oncologist. 2022-04-05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: